Related Experiment Video
Updated: May 3, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
14.2K
Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma
Satoshi Ichikawa1, Noriko Fukuhara, Hiroki Katsushima
1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Cancer Science
|January 24, 2014
Summary
BACH2 expression levels can predict prognosis in diffuse large B cell lymphoma (DLBCL). High BACH2 expression is linked to shorter survival rates in DLBCL patients, particularly in specific subtypes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- BACH2 is a B cell-specific transcriptional repressor crucial for B cell maturation.
- The prognostic significance of BACH2 expression in diffuse large B cell lymphoma (DLBCL) requires further validation.
Purpose of the Study:
- To investigate the clinicopathological significance of BACH2 expression as a prognostic predictor in DLBCL.
- To correlate BACH2 expression levels with patient outcomes in different DLBCL subtypes.
Main Methods:
- Immunohistochemical analysis of BACH2 expression in 94 DLBCL cases.
- Subclassification of DLBCL into germinal center B cell (GCB) and non-GCB phenotypes.
- Analysis of MYC gene alteration (MYC+) status.
Main Results:
- High BACH2 expression was associated with significantly shorter 3-year overall survival (OS) in both GCB and non-GCB groups (71.7% vs 91.3%, P = 0.0256).
- In the MYC+ group, cases with low BACH2 expression demonstrated better survival outcomes.
- No significant differences in clinical characteristics or outcomes were observed between GCB and non-GCB groups initially.
Conclusions:
- BACH2 expression level is a promising independent predictor of prognosis in DLBCL.
- Targeting BACH2 expression may offer therapeutic strategies for improving DLBCL patient outcomes.
